ALGS

Aligos Therapeutics, Inc. (ALGS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Aligos Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for liver diseases (chronic Hepatitis B virus, MASH) and viral infections (coronaviruses). The company has no products approved for commercial sale and has incurred significant losses since inception. As of March 31, 2026, the company had 6,188,223 shares of common stock outstanding, including 800,000 non-voting shares.

Key Financial Metrics

Note: Q1 2025 net income was significantly inflated by a $61.5 million non-cash gain from the change in fair value of 2023 Common Warrants. Q1 2026 included a $3.4 million non-cash gain from the same instrument.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased 810% to $2.8 million, driven primarily by a $3.0 million milestone payment from Amoytop Biotech for the initiation of IND-enabling studies on a collaboration compound.
• Expense Growth: Total operating expenses rose 52% to $29.8 million. Research and Development (R&D) expenses increased 61% to $23.4 million, largely due to the commencement of the Phase 2 B-SUPREME clinical trial for pevifoscorvir sodium.
• Volatility in Non-Operating Items: The change in fair value of 2023 Common Warrants decreased from a $61.5 million gain in Q1 2025 to a $3.4 million gain in Q1 2026, reflecting changes in the company's stock price and volatility assumptions.
• Liquidity Position: Total cash and short-term investments decreased by approximately $23 million compared to the prior year-end, primarily due to operating cash burn and the maturity of short-term investments without immediate reinvestment.

Guidance, Outlook, and Risks

• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management expects current cash, cash equivalents, and short-term investments ($54.9 million) to fund operations only into the fourth quarter of 2026, inclusive of an expected $25 million upfront payment from a new Amoytop agreement.
• Subsequent Event: In April 2026, Aligos entered an exclusive license agreement with Amoytop for pevifoscorvir sodium in Greater China, securing a $25 million upfront payment and up to $420 million in potential milestones.
• Clinical Progress:
  • Pevifoscorvir sodium (HBV): Phase 2 B-SUPREME study is enrolling. An interim analysis in April 2026 recommended increasing the sample size for the HBeAg- cohort.
  • ALG-055009 (MASH/Obesity): Phase 2a HERALD study met primary endpoints with significant liver fat reduction. Preclinical data suggests synergy with incretin receptor agonists for weight loss.
  • ALG-097558 (Coronavirus): Phase 2 AGILE trial is ongoing, supported by NIH funding.
• Risks: Key risks include the need for substantial additional financing, potential failure of clinical trials, regulatory delays, and the impact of the U.S. BIOSECURE Act on third-party manufacturing relationships.

Investor Verification Checklist

• Cash Runway: Verify the timing and certainty of the $25 million Amoytop upfront payment to confirm if it extends the runway beyond Q4 2026.
• Capital Needs: Assess the company's plan for raising additional capital given the "substantial doubt" disclosure and the high burn rate ($23.1 million operating cash outflow in Q1).
• Warrant Liability: Monitor the fair value of the 2023 Common Warrants ($8.8 million liability), as fluctuations will continue to impact reported net income/loss.
• Clinical Milestones: Track enrollment rates and interim data readouts for the Phase 2 B-SUPREME study, which is the primary driver of current R&D spend.
• Regulatory Environment: Evaluate potential impacts of the U.S. BIOSECURE Act and new tariffs on the company's reliance on third-party manufacturers and CROs.